D. A. approval for that purpose wouldenableGenentechto advertiseandpromote the drugas abreast cancertreatment and probablymakeinsurersmore willing to pay forit.
Biotechs now have renewed interest in these structures because it can enable them to advance development of drug candidates before it licenses them to Big Pharma.